Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration

NCT04058535 is registered in ClinicalTrials.gov with Alteogen, Inc. as lead sponsor.

NCT NCT04058535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04058535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
Alteogen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 5, 2020
Completion date
December 22, 2020
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration